Abstract
Thyroid cancer is a common malignancy with an apparent increasing incidence and a wide spectrum of clinical behavior and therapeutic responsiveness. Recent advances in diagnosis, primary treatment, and long-term monitoring have led to enhanced detection of primary and recurrent disease and improvements in therapy. Controversy still surrounds several issues: the most accurate predictive staging system and histological subclassification scheme, optimal preoperative assessment and surgical extent, appropriate use of radioiodine for remnant ablation, goal for thyrotropin-suppressive thyroid hormone therapy, best practices in immediate postoperative and long-term monitoring, and approach to the patient with thyroglobulin evidence of residual disease. In this paper, recent data related to these controversial issues are critically reviewed.
Original language | English (US) |
---|---|
Pages (from-to) | 97-116 |
Number of pages | 20 |
Journal | Endocrine-related cancer |
Volume | 11 |
Issue number | 1 |
DOIs | |
State | Published - Mar 2004 |
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Oncology
- Endocrinology
- Cancer Research